Chemosensitivity of human malignant glioma: Modulation by p53 gene transfer

被引:45
作者
Trepel, M
Groscurth, P
Malipiero, U
Gulbins, E
Dichgans, J
Weller, M
机构
[1] Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany
[2] Univ Tubingen, Sch Med, Dept Physiol, D-72076 Tubingen, Germany
[3] Univ Zurich, Sch Med, Inst Anat, Zurich, Switzerland
[4] Univ Zurich, Sch Med, Clin Immunol Sect, Zurich, Switzerland
关键词
tumor suppressor gene; p53; chemoresistance; gene therapy; apoptosis;
D O I
10.1023/A:1005910323338
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Loss of wild-type p53 activity is one of the most common molecular abnormalities in human cancers including malignant gliomas. The p53 status is also thought to modulate sensitivity to irradiation and chemotherapy. Here, we studied the effect of a p53 gene transfer on the chemosensitivity of three human glioma cell lines with different endogenous p53 status (LN-229, wild-type; LN-18, mutant; LN-308, deleted), using the murine temperature-sensitive p53 val(135) mutant. Expression of mutant p53 enhanced proliferation of LN-308 cells but reduced proliferation in the other cell lines. Expression of wild-type p53 caused reversible growth arrest of all cell lines but failed to induce apoptosis. Growth arrest induced by wild-type p53 was associated with strong induction of p21 expression. Strong induction of BAX expression and loss of BCL-2 expression, which are associated with p53-dependent apoptosis rather than growth arrest, were not observed. Wild-type p53 failed to sensitize glioma cells to cytotoxic drugs including BCNU, cytarabine, doxorubicin, teniposide and vincristine. The combined effects of wild-type p53 gene transfer and drug treatment were less than additive rather than synergistic, suggesting that the intracellular cascades activated by p53 and chemotherapy are rebundant. Unexpectedly, forced expression of mutant p53 modulated drug sensitivity in that it enhanced the toxicity of some drugs but attenuated the effects of others. These effects may represent a dominant negative effect of mutant p53 in LN-229 cells which have wild-type p53 activity but must be considered a gain of function-type effect in the other two cell lines which have no wild-type p53 activity. Importantly, no clear-cut pattern emerged among the three cell lines studied. We conclude that somatic gene therapy based on the reintroduction of p53 will limit the proliferation of human malignant glioma cells but is unlikely to induce clinically relevant sensitization to chemotherapy in these tumors.
引用
收藏
页码:19 / 32
页数:14
相关论文
共 58 条
[1]   ADENOVIRUS-MEDIATED P53 GENE DELIVERY INHIBITS 9L GLIOMA GROWTH IN RATS [J].
BADIE, B ;
DRAZAN, KE ;
KRAMAR, MH ;
SHAKED, A ;
BLACK, KL .
NEUROLOGICAL RESEARCH, 1995, 17 (03) :209-216
[2]   MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].
BARAK, Y ;
JUVEN, T ;
HAFFNER, R ;
OREN, M .
EMBO JOURNAL, 1993, 12 (02) :461-468
[3]  
Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO
[4]  
2-6
[5]   THE P53 GENE AND ITS ROLE IN HUMAN BRAIN-TUMORS [J].
BOGLER, O ;
HUANG, HJS ;
KLEIHUES, P ;
CAVENEE, WK .
GLIA, 1995, 15 (03) :308-327
[6]  
BRACHMAN DG, 1993, CANCER RES, V53, P3667
[7]   P53-DEPENDENT APOPTOSIS IN THE ABSENCE OF TRANSCRIPTIONAL ACTIVATION OF P53-TARGET GENES [J].
CAELLES, C ;
HELMBERG, A ;
KARIN, M .
NATURE, 1994, 370 (6486) :220-223
[8]  
EASTHAM JA, 1995, CANCER RES, V55, P5151
[9]  
ELDEIRY WS, 1994, CANCER RES, V54, P1169
[10]  
ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217